$NNVC News

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

NanoViricides closes $2M direct offering

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

NanoViricides to raise $2M in registered direct offering

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

NanoViricides Prices Sale Of 1,333,334 Shares And Warrants For Gross Proceeds Of ~$2M

NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

NanoViricides' Clinical Stage, Broad-Spectrum, Antiviral Drug NV-387 Granted Orphan Drug Designation By US FDA Office Of Orphan Products Development

NanoViricides Granted FDA Orphan Drug Designation Status For Treatment Of The Measles Virus

NanoViricides says NV-387 could address measles outbreaks as cases rise globally

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI